These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34242790)

  • 1. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
    Hann CL; Burns TF; Dowlati A; Morgensztern D; Ward PJ; Koch MM; Chen C; Ludwig C; Patel M; Nimeiri H; Komarnitsky P; Camidge DR
    J Thorac Oncol; 2021 Sep; 16(9):1582-1588. PubMed ID: 34242790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
    Johnson ML; Zvirbule Z; Laktionov K; Helland A; Cho BC; Gutierrez V; Colinet B; Lena H; Wolf M; Gottfried M; Okamoto I; van der Leest C; Rich P; Hung JY; Appenzeller C; Sun Z; Maag D; Luo Y; Nickner C; Vajikova A; Komarnitsky P; Bar J
    J Thorac Oncol; 2021 Sep; 16(9):1570-1581. PubMed ID: 33823285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
    Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
    J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
    Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
    Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
    Calvo E; Spira A; Miguel M; Kondo S; Gazzah A; Millward M; Prenen H; Rottey S; Warburton L; Alanko T; Cassier PA; Yoh K; Italiano A; Moreno V; Peltola K; Seto T; Toyozawa R; Afar DE; Englert S; Komarnitsky P; Lambert S; Parikh A; Vosganian G; Gao B
    Cancer Treat Res Commun; 2021; 28():100405. PubMed ID: 34329846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
    Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
    Malhotra J; Nikolinakos P; Leal T; Lehman J; Morgensztern D; Patel JD; Wrangle JM; Curigliano G; Greillier L; Johnson ML; Ready N; Robinet G; Lally S; Maag D; Valenzuela R; Blot V; Besse B
    J Thorac Oncol; 2021 Sep; 16(9):1559-1569. PubMed ID: 33652156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
    Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer.
    Goldman JW; Barve M; Patel JD; Wozniak A; Dowlati A; Starodub A; Owonikoko TK; Edenfield W; Laurie SA; Da Costa D; Lally S; Koch M; Kosloski MP; Hoffman D; Dy GK
    Clin Transl Sci; 2021 Mar; 14(2):664-670. PubMed ID: 33340277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
    Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
    Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
    Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer.
    Lindner DJ; Wildey G; Parker Y; Dowlati A; Stark GR; De S
    Br J Cancer; 2021 Mar; 124(5):893-895. PubMed ID: 33257843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
    Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
    EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DLL3: an emerging target in small cell lung cancer.
    Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
    J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
    Owonikoko TK; Dahlberg SE; Sica GL; Wagner LI; Wade JL; Srkalovic G; Lash BW; Leach JW; Leal TB; Aggarwal C; Ramalingam SS
    J Clin Oncol; 2019 Jan; 37(3):222-229. PubMed ID: 30523756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.